DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SODIUM ACETATE ANHYDROUS

« Back to Dashboard

Clinical Trials for Sodium Acetate Anhydrous

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00283387	Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	The aim of this study is to assess the efficacy and safety of betaine in reducing urine oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients. Hypothesis: Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I patients.
NCT00283387	Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria	Completed	Orphan Europe	Phase 2	The aim of this study is to assess the efficacy and safety of betaine in reducing urine oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients. Hypothesis: Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I patients.
NCT00283387	Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria	Completed	Mayo Clinic	Phase 2	The aim of this study is to assess the efficacy and safety of betaine in reducing urine oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients. Hypothesis: Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I patients.
NCT00302289	B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients	Completed	Science, Toxicology & Technology, San Francisco, California	Phase 1	The primary aim was to measure the effect of green tea extract, tyrosine and caffeine on energy expenditure, appetite ratings and spontaneous energy intake together with recording of side effects in healthy normal weight subjects.
NCT00302289	B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients	Completed	University of Copenhagen	Phase 1	The primary aim was to measure the effect of green tea extract, tyrosine and caffeine on energy expenditure, appetite ratings and spontaneous energy intake together with recording of side effects in healthy normal weight subjects.

Clinical Trial Conditions for Sodium Acetate Anhydrous

Condition Name

Condition Name for Sodium Acetate Anhydrous
Intervention	Trials
Healthy	4
Patients Undergoing Screening or Surveillance Colonoscopy	1
Congenital Cytomegalovirus	1
Parkinson's Disease	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sodium Acetate Anhydrous
Intervention	Trials
Pediatric Obesity	1
Rhinitis	1
Obesity	1
Tension-Type Headache	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sodium Acetate Anhydrous

Trials by Country

Trials by Country for Sodium Acetate Anhydrous
Location	Trials
United States	23
United Kingdom	5
Canada	3
Denmark	1
Australia	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sodium Acetate Anhydrous
Location	Trials
Utah	2
North Carolina	2
New York	2
Alabama	2
Pennsylvania	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sodium Acetate Anhydrous

Clinical Trial Phase

Clinical Trial Phase for Sodium Acetate Anhydrous
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sodium Acetate Anhydrous
Clinical Trial Phase	Trials
Completed	11
Unknown status	2
Not yet recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sodium Acetate Anhydrous

Sponsor Name

Sponsor Name for Sodium Acetate Anhydrous
Sponsor	Trials
Ranbaxy Laboratories Limited	2
Ferring Pharmaceuticals	2
University of Alabama at Birmingham	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sodium Acetate Anhydrous
Sponsor	Trials
Other	13
Industry	11
NIH	1

Export unavailable in trial.
Subscribe for complete access.